Opioid Use Disorder (OUD) Global Market Report 2023 – By Drug Type (Buprenorphine, Naltrexone, Methadone), By Route of Administration (Oral, Parenteral), By Age Group (19 To 40, 41 To 60, 61 And Over), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies And Stores, Online Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

A used truck is one that has previously been owned and is being resold to a new customer. They are used for several purposes, including transporting products and supplies, hauling cargo, doing construction work, and towing trailers. The main types of used trucks are light-duty trucks, medium-duty trucks, and heavy-duty trucks. A light-duty truck is a vehicle classification used for trucks and vehicles with a gross vehicle weight of up to 8,500 pounds and a payload capacity of up to 4,000 pounds. They are available in various fuel types, such as gasoline, electric, and diesel. They are available through sales channels such as franchised dealers, independent dealers, and peer-to-peer, and are utilized by various end-users, such as construction, oil and gas, mining, and others. The global used truck market is segmented - 1) By Type: Light-Duty Truck, Medium-Duty Truck, Heavy-Duty Truck 2) By Fuel Type: Gasoline, Electric, Diesel 3) By Sales Channel: Franchised Dealer, Independent Dealer, Peer-To-Peer 4) By End-Use: Construction, Oil And Gas, Mining, Other End-Users The global used trucks market is expected to grow from $42.59 billion in 2022 to $45.39 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The used trucks market is expected to reach $58.12 billion in 2027 at a CAGR of 6.4%. The rise in the construction industry is expected to propel the growth of the used truck market going forward. The construction industry is the industrial segment of production and commerce concerned with constructing, repairing, renovating, and maintaining infrastructures. Used trucks are used for transporting several construction materials on construction sites. For instance, in June 2021, according to the NZ Tauranga Aotearoa, a New Zealand-based government data agency, building activities increased by 3.7% in March 2021. Further, in 2021, residential activities rose 4.3% compared to 2020. Additionally, according to the US Census Bureau, the value of construction activities increased from $1,626.4 billion in 2021 to $1,792.9 billion in 2022, with a growth rate of 10.2%. Therefore, the rise in the construction sector drives the used truck market. Major players in the used truck market are Mercedes Benz AG, Daimler Truck AG, Charter Trucks Co, Renault SA, AB Volvo, PACCAR Inc., Penske Automotive Group, MAN SE, Ryder System Inc.,Scania AB, Navistar International Corporation, Hertz Car Sales, Schneider National Inc.,Ruan Transportation Management Systems Inc., Murphy-Hoffman Co, Premier Truck Group, Freightliner Trucks, Kenworth Truck Company, Ritchie Bros, The Larson Group, TruckPaper.com, Del-Val International Trucks Inc., Arrow Truck Sales Inc., Fyda Freightliner Inc., Peterbilt Motors Company, Vander Haag's Inc., Mascus International Holding Co, and Hammer Trucks Sales LLC. Introducing innovative used truck brands and sites is a key trend for gaining popularity in the used truck market. Major companies operating in the used truck market are focused on developing innovative solutions to strengthen their position in the market. For instance, in June 2023, Daimler, a Germany-based automotive manufacturer, launched Bharat Benz Certified brand for used trucks. Customers can choose a new annual maintenance contract (AMC) while purchasing used Bharat Benz trucks. Furthermore, in May 2021, Volvo AB, a Sweden-based commercial vehicle designer, manufacturer, and supplier, launched Volvo Selected, a new European e-commerce site for purchasing old trucks. Volvo Trucks intends to encourage sustainability and circularity by making it easier and less time-consuming for clients to identify the right secondhand vehicle that has passed all required inspections and assessments. The vehicles may be delivered anywhere in the world, and the trucks come with driveline coverage, service contracts, and flexible financing options. In April 2021, Nesco Holdings Inc, a US-based manufacturer of specialist equipment, parts, tools, accessories, and services, acquired Custom Truck One Source LP in collaboration with an affiliate of Platinum Equity LLC, a US-based private equity firm for $1.475 billion. With this acquisition, both companies aim to create a leading one-stop shop for specialty rental equipment, serving highly attractive and growing infrastructure markets such as transmission and distribution energy grids, 5G revolution build-out, critical rail, and other national infrastructure initiatives. Custom Truck One Source LP (Custom Truck) is a US-based single-source manufacturer and provider of specialized vehicle and heavy equipment solutions, providing an extensive rental fleet, new and used truck sales, and aftermarket parts. Asia-Pacific was the largest region in the used truck market in 2022. The regions covered in used truck report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the used truck market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The used truck market consists of sales of pickup trucks, cement trucks, chiller trucks, crane trucks or mobile cranes, fire trucks, logging trucks, snow plows, and tankers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The used truck market research report is one of a series of new reports from The Business Research Company that provides used truck market statistics, including used truck industry global market size, regional shares, competitors with a used truck market share, detailed used truck market segments, market trends and opportunities, and any further data you may need to thrive in the used truck industry. This used truck market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Substance abuse is referred to as a habit of compulsive substance use characterized by recurring substantial social, occupational, legal, or interpersonal negative outcomes such as missed work or school, arrests, and marriage problems. Addiction is defined as a psychological or physical dependence on alcohol or other drugs. Substance abuse and addiction are the use of illegal substances, prescription or over-the-counter medications, or alcohol for purposes other than those intended or in excessive quantities. The major abuse types for substance abuse and addiction treatment are alcohol dependence, tobacco or nicotine addiction, and others. Drug abuse refers to the use of specific chemicals with the intent of producing pleasurable effects on the brain. Such treatments include alcohol addiction treatment, tobacco or nicotine addiction treatment, opioid addiction treatment, and others. Major distribution channels involved are hospital pharmacies, retail pharmacies, and others. The global substance abuse and addiction treatment market is segmented - 1) By Abuse Type: Alcohol Dependence, Tobacco or Nicotine Addiction, Other Abuse Types 2) By Treatment: Alcohol Addiction Treatment, Tobacco or Nicotine Addiction Treatment, Opioid Addiction Treatment, Other Treatments 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels The global substance abuse and addiction treatment market size is expected to grow from $9.80 billion in 2022 to $10.90 billion in 2023 at a compound annual growth rate (CAGR) of 11.21%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The substance abuse and addiction treatment market size is expected to reach $15.88 billion in 2027 at a CAGR of 9.8%. A high prevalence of alcohol use is expected to boost the growth of the substance abuse and addiction treatment market going forward. Alcohol use refers to consuming ethyl alcohol-containing beverages. The increased prevalence of alcohol use disorders causing substance use disorders, which increased the demand for substance abuse and addiction treatment. For instance, in August 2022, according to data published by RTI International, a US-based non-profit organization, alcohol consumption in November 2020 was 39% higher than in February 2020. As well, binge drinking increased by 26% between February and April 2020 and by 30% between February and November 2020. Therefore, the high prevalence of alcohol use is driving the growth of the substance abuse and addiction treatment market. Major players in the substance abuse and addiction treatment market are Alkermes, Indivior Plc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mallinckrodt Plc., GlaxoSmithKline Plc., Purdue Pharma LP., Allergan Plc., BioCorRx Inc., Accord Healthcare, Abbvie Inc., Cipla Ltd., Sanofi SA, Novartis AG (Sandoz), and Noramco. New product innovation has emerged as the key trend gaining popularity in the substance abuse and addiction treatment market. Major companies operating in the substance abuse and addiction treatment market are developing innovative products to strengthen their position in the market. For instance, in September 2021, Lyra Health, a US-based provider of innovative mental healthcare benefits, launched its first technology-integrated care solutions. The unique features of integrated care solutions Lyra Reset include virtual counseling to help stop drinking or achieve sobriety, digital lessons, and medication to combat cravings, all of which serve to reduce the impact of stigma. This first technology—integrated care solutions—is designed to address major mental health concerns like alcohol use disorder (AUD), suicidality, and other complicated mental health conditions. In November 2021, Odyssey Behavioral Healthcare, a US-based mental health services company, acquired CIVIQ Health for an undisclosed amount. This acquisition increases Odyssey's ability to treat dual diagnoses and addiction, and it offers detoxification treatments with the capability to meet rising market demand. CIVIQ Health is a US-based healthcare company that provides a long-term drug treatment program to aid in overcoming addiction's challenges. North America was the largest region in the substance abuse and addiction market in 2022. The regions covered in the global substance abuse and addiction treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the substance abuse and addiction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The substance abuse and addiction treatment market includes revenues earned by entities by providing treatment for dipsomania, narcotics abuse, alcoholism, and solvent abuse. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The substance abuse and addiction treatment market research report is one of a series of new reports from The Business Research Company that provides substance abuse and addiction treatment market statistics, including substance abuse and addiction treatment industry global market size, regional shares, competitors with a substance abuse and addiction treatment market share, detailed substance abuse and addiction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the substance abuse and addiction treatment industry. This substance abuse and addiction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A pain management drug refers to medication that reduces pain. They produce analgesia by actions at several levels of the nervous system such as, inhibition of neurotransmitter release from the primary afferent terminals in the spinal cord and activation of descending inhibitory controls in the midbrain. The main class of pain management drugs are non-steroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. NSAID refers to a nonsteroidal anti-inflammatory drug. It is used to lower a high fever, lessen inflammation, and ease discomfort. These are used for various indications such as arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, and others, which are distributed by different channels including hospital pharmacies, retail pharmacies, and online pharmacies. The global pain management drugs market is segmented - 1) By Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics 2) By Indication: Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle sprain/strain, Bone fracture, Other Indications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global pain management drugs market size is expected to grow from $72.60 billion in 2022 to $76.76 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pain management drugs market size is expected to reach $92.15 billion in 2027 at a CAGR of 4.7%. The rise in the geriatric population is expected to boost the growth of the pain management drugs market going forward. The geriatric population refers to people 65 years and older. Pain management drugs are often given to elderly patients to relieve the pain of arthritis, cancer, neurological disorders, and other conditions that are more common in later life; hence, the rise in the geriatric population is expected to boost the pain management drugs market. For instance, in October 2022, according to a report published by World Health Organization (WHO), a Switzerland -based agency responsible for international public health, one in six persons in the whole world will be 60 years of age or older by the year 2030. The number of individuals over 60 in the world will double (2.1 billion) by 2050. Additionally, between 2020 and 2050, there will be 426 million more people who are 80 years of age or older than there are today. Therefore, the rise in the geriatric population is driving the growth of the pain management drugs market. Major players in the pain management drugs market are Novartis AG, Eli Lilly And Company, Abbott Laboratories, Endo International plc, Purdue Pharma L.P., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., GlaxoSmithKline plc, AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Mylan N.V., and Bausch Health Companies Inc. Technological advancement is the key trend gaining popularity in the pain management drugs market. Major companies operating in the pain management drugs market are focusing on developing new technologies. For instance, in November 2021, AppliedVR, Inc., a US-based company that offers virtual reality therapeutics, launched EaseVRx, a prescription-only immersive virtual reality (VR) system that helps patients with chronic lower back pain, who are 18 years of age and older, reduce their pain by utilizing cognitive behavioural therapy and other behavioural techniques. The unique feature of EaseVRx is its use of CBT and other behavioural treatment techniques to reduce pain and pain interference. The EaseVRx treatment program consists of 56 VR sessions that range in length from 2 to 16 minutes and are designed to be used daily for eight weeks of treatment. A skills-based treatment program is used in the device's VR software, which applies well-established behavioural therapy principles to alleviate the physiological symptoms of pain. In August 2020, Acadia Pharmaceuticals Inc., a US-based biotechnology company, acquired CerSci Therapeutics for $52.5 million. This acquisition expands Acadia's clinical pipeline by adding non-opioid pain medicines with possible non-addictive qualities and decreased adverse effects commonly associated with current opioid treatments. CerSci Therapeutics is a US-based clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. North America was the largest region in the pain management drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global pain management drug market report during the forecast period. The regions covered in the global pain management drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pain management drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The pain management drug market consists of sales of acetaminophen, anti-seizure medications, steroids, muscle relaxers, and other related drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The pain management drugs market research report is one of a series of new reports from The Business Research Company that provides pain management drugs market statistics, including pain management drugs industry global market size, regional shares, competitors with a pain management drugs market share, detailed pain management drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pain management drugs industry. This pain management drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An oral thin film (OTF) is a very thin polymeric film that is applied in the mouth. The purpose of oral thin film (OTF) is to deliver therapeutic substances into the oral cavity or the stomach tract, where they are absorbed and transported directly to the circulatory system. The main types of oral thin films include sublingual film and fast dissolving dental/buccal film. The sublingual film refers to oral thin films that rapidly dissolve under the tongue and are quickly absorbed by blood with the help of tissue. It is used to treat patients who are recovering from opioid misuse disorder. These oral thin films are used in the treatment of schizophrenia, migraine, opioid dependence, nausea, and vomiting. They are sold through hospital pharmacies, retail pharmacies, and other distribution channels. The global oral thin films market is segmented - 1) By Type: Sublingual Film, Fast Dissolving Dental/Buccal Film 2) By Disease Indication: Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting, Other Disease Indication 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels The global oral thin films market size grew from $3.58 billion in 2022 to $3.99 billion in 2023 at a compound annual growth rate (CAGR) of 11.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the oral thin films market is expected to grow to $6.22 billion in 2027 at a CAGR of 11.7%. Rising demand for thin film drug delivery systems is propelling the growth of the oral thin film market. Thin films have been identified as a potential alternative to standard dosage forms. It is a convenient, self-administrable, and fast-dissolving dosage form for the delivery of medications, which makes it a versatile drug delivery platform. Thin films are taken orally and do not require water to be swallowed to absorb a drug. OTF is more patient-friendly due to its rapid dissolution rate. Due to these reasons, the demand for thin-film drug delivery systems is increasing, which is bringing more demand for oral thin films as well. For instance, in January 2021, a Turkish Journal of Pharmaceutical Sciences report shows that the global thin-film pharmaceutical products market is expected to increase from $7 billion in 2015 to over $15 billion by the end of 2024. It estimates that there will be an increase of 117% in 10 years. Thus, increasing demand for thin film drug delivery systems is driving the growth of the oral thin film market. Major players in the oral thin films market are ZIM Laboratories, NAL Pharma, Cure Pharmaceutical, IntelGenx Corp., Kyu Kyu Pharmaceutical Co. Ltd., Seoul Pharmaceuticals, CL Pharm, Aquestive Therapeutics Inc., Shilpa Therapeutics Pvt. Ltd., Sunovion Pharmaceuticals Inc., Solvay, LTS Lohmann Therapie-Systeme AG, Mylan Inc., LIVKON Pharmaceuticals Pvt. Ltd., and ARx, LLC. The rapidly growing investment in research and development (R&D) by leading players has propelled the growth of the oral thin film market. Major companies operating in the oral thin films market are focused on investing in research and development of fast dissolving oral thin films to strengthen their position by implementing new platform technologies such as soluleaves, XGEL, and waferTab. R&D helps to innovate new solutions that can be more convenient, effective, and efficient for drug delivery. For instance, in October 2020, CURE Pharmaceutical Holding Corp. introduced Nutri-Strips, a revolutionary oral thin-film strip technology to enhance efficiency over OTC vitamins, capsules, soft gels, and gummies for a better consumer experience. As part of its R&D efforts, the company has developed a broad platform of formulations that offer targeted dosing, including CURE’s patented and advanced oral thin-film strip technology. In September 2022, LTS LOHMANN Therapie-Systeme AG, a Germany-based company specializing in the development and manufacture of drug delivery systems such as oral thin films (OTF), acquired Tapemark Inc. for an undisclosed amount. With this acquisition, LTS leveraged Tapemark's premier CDMO with expertise in oral thin film, unit dosage semi-solid drugs, and iontophoresis products. Tapemark Inc. is a US-based CDMO specializing in transdermal drug delivery systems and oral thin film. North America was the largest region in the oral thin film market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral thin film market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the oral thin film market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The oral thin films market consists of sales of orally disintegrating and orally dissolving films. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The oral thin films market research report is one of a series of new reports from The Business Research Company that provides oral thin films market statistics, including oral thin films industry global market size, regional shares, competitors with an oral thin films market share, detailed oral thin films market segments, market trends and opportunities, and any further data you may need to thrive in the oral thin films industry. This oral thin films market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The used cars refer to cars, which are preowned by one or more owners. The used cars are generally purchased due to budget restrictions and by first-time buyers. In addition to that, a used car has an advantage over a new car as it depreciates at a slower pace. Particularly for first time car buyers, a used buying is more useful and affordable at the same time. The main types of used cars include hatchbacks, sedans, and SUVs. The hatchback cars are small boxy type passenger cars with a two-compartment configuration and fold-out cargo door. These used cars are fueled by petrol, diesel, and hybrid/electric and sold through peer-to-peer platforms, franchised dealers and independent dealers. The global used cars market is segmented - 1) By Vehicle Type: Hatchback, Sedan, SUV 2) By Fuel Type: Petrol, Diesel, Hybrid/Electric 3) By Sales Channel: Peer-To-Peer, Franchised Dealers, Independent Dealers The global used cars market size will grow from $1243.34 billion in 2022 to $1339.73 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global used cars is expected to grow to $1899.97 billion in 2027 at a CAGR of 9.1%. The emergence of online platforms for used car sales globally is significantly driving the growth of the used cars market. The online platforms provide ease of access and required information to buy and sell used cars. The key players are expanding their business digitally to increase the sales of used cars. For instance, in September 2021, Ola launched a used automobile marketplace named 'Ola Cars,' which will allow customers to buy, and trade used cars. It will also provide 'try and buy’ services from the comfort of customers' homes, as well as simple financing with EMI alternatives and a one-year warranty. These kinds of new online platforms provide convenience for the buyers to choose from a variety of options irrespective of their locations and invariably increase the sales of used cars. Hence, the emergence of online platforms is expected to propel the growth of the used cars market over the coming years. Major players in the used cars market are Hendrick Automotive Group, Group 1 Automotive, Inc., Cox Automotive, Asbury Automotive Group, Inc., CarMax Business Services LLC, TrueCar, Inc., Pendragon PLC, Lithia Motors, Inc., The Hertz Corporation, AutoNation, Quikr, Honda Auto Terrace, Toyota U-Trust, Vroom, OLX, Cars24 services private limited, Big Boy Toyz Ltd., Alibaba.com, Scout24 AG. Increasing investment in the market is a key trend gaining popularity in the used cars market. Major companies operating in the used cars market are focused on increasing investments for business expansions and strengthening their business position. For instance, in December 2020, Volkswagen, a leading motor vehicle manufacturer based in Germany announced the expansion of its digitally connected pre-owned automobile dealership network in India with the opening of two new locations, one each in Ahmedabad and Bengaluru. In addition, the automaker reiterated its intention to open 21 such dealerships that will increase its focus on the used cars business investments. In October 2021, Constellation Automotive Group, based in England, a key player in the digital marketplace for used cars in Europe has announced the acquisition of CarNext for an undisclosed amount. As a result of this acquisition, Constellation Automotive Group aims to expand its business rapidly and reach 2.5 million car sales annually. CarNext is a Netherlands-based company that provides a marketplace for used cars in several European countries. Asia-Pacific was the largest region in the used cars market in 2022 and is expected to be the fastest-growing region in the forecast period. The regions covered in the global used cars market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the used cars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The used cars market consists of sales of hybrid, sedan, coupe, convertible, CUV, wagon, and van. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The used cars market research report is one of a series of new reports from The Business Research Company that provides used cars market statistics, including used cars industry global market size, regional shares, competitors with a used cars market share, detailed used cars market segments, market trends and opportunities, and any further data you may need to thrive in the used cars industry. This used cars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Analgesics are the pain killers that are used to treat mild or severe pain, including musculoskeletal pain, surgical, trauma pain, cancer pain, or another type of pain. Examples of analgesics include codeine, hydrocodone, oxycodone, and methadone. The different types of analgesics are non-opioids and opioids. Non-opioid analgesics are pain relievers available over-the-counter (OTC) and by prescription. They are rapidly being promoted as a desirable, safe, and productive first-line therapeutic alternative to opioid drugs in a range of clinical settings for mild to severe acute and chronic pain. The different types of drugs include prescription analgesics, and OTC analgesics and involve various routes of administration, such as oral, intravenous, rectal, transdermal, and topical. It is used in internal analgesics, and external analgesics and distributed through various channels, such as hospital pharmacies, retail pharmacies, and drug stores. The global analgesics market is segmented – 1) By Type: Non-opioids, Opioids 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores 3) By Route of Administration: Oral, Intravenous, Rectal, Transdermal, Topical 4) By Drug Type: Prescription Analgesics, OTC Analgesics 5) By Application: Internal Analgesics, External Analgesics The global analgesics market size will grow from $111.15 billion in 2022 to $115.13 billion in 2023 at a compound annual growth rate (CAGR) of 3.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size for the global analgesics size is expected to grow to $127.80 billion in 2027 at a CAGR of 2.6%. A significant rise in the prevalence of chronic diseases is driving the analgesics Market. Analgesic drugs, also known as painkillers, are used to treat and reduce chronic or severe pain in the body resulting from various medical conditions. For instance, in September 2022, according to a report shared by WHO, a Switzerland-based health organization, chronic diseases which is sometimes referred to as noncommunicable diseases (NCDs), are conditions that develop over an extended period of time as a result of a combination of genetic, physiological, environmental, and behavioural variables. Noncommunicable diseases (NCDs) account for 41 million annual fatalities, or 74% of all fatalities worldwide. Before the age of 70, 17 million individuals per year pass away from an NCD. These untimely deaths account for 86% of the deaths in low- and middle-income nations. 77% of NCD-related deaths occur in low- and middle-income nations. Therefore, significant rise in the prevalence of chronic disease is driving the growth of the analgesics market. Major players in the analgesics market are Bayer Healthcare, Pfizer, Sanofi, Johnson & Johnson, Novartis AG, GlaxoSmithKline PLC., Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly and Company. The growth of the analgesics market is restricted by the increasing use of biologics for the treatment of inflammatory and neuropathic pain. Biologics are drugs produced from living organisms and include several components derived from humans, animals, or microorganisms. These drugs may contain protein, modified human hormones, or cells that produce substances that suppress or activate parts of the immune system. Biologics can provide greater efficacy compared to analgesics, which provide effective pain relief to only 50% of the patients, and is thus widely used nowadays. Rising demand for biologics can adversely impact the growth of the Analgesics market. For instance, Pfizer and Lilly were granted approval by the FDA for developing Tanezumab, a biologics medicine. Companies in the analgesics market are increasingly focusing on acquisition as a strategy for growth. Leading analgesic drug manufacturers are acquiring smaller companies to gain a competitive advantage and strengthen their market position. These acquisitions are helping companies to expand geographically and gain specialized expertise in the research and development of new products. For instance, Analgesic Solutions, LLC was acquired by WCG. WCG intends to make use of the superior R&D capability of Analgesic Solutions, LLC to grow and position itself as a market leader in the Analgesic Market. The US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare Products Regulatory Agency are some of the regulatory bodies that regulate the Analgesic Market. For instance, the FDA has provided guidelines on the manufacturing process of analgesics, and safety measures regarding the use of both opioid and non-opioid analgesics. FDA also regulates and monitors the misuse and abuse of opioid analgesics. Opioid analgesics are prohibited from being sold without a proper medical prescription. Similarly, the Medicines and Healthcare Products Regulatory Agency in the UK safeguards the public interest through effective regulation of analgesic drugs. WCG, a US-based pharmaceuticals company, acquired Analgesic Solutions, LLC, for an undisclosed amount. WCG's newest acquisition aims to improve test sensitivity in clinical trials, through advising, novel tools, data science, technology, and specialised training. Analgesic Solutions, LLC, is a US-based pharmaceutical company that specialises in the development of new pain medications. North America was the largest region in the analgesics market in 2022. Middle East is expected to be the fastest-growing region in the global analgesics market during the forecast period. The regions covered in the global analgesics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the analgesics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The analgesics market consists of sales of codeine, hydrocodone, oxycodone, and methadone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The analgesics market research report is one of a series of new reports from The Business Research Company that provides analgesics market statistics, including analgesics industry global market size, regional shares, competitors with an analgesics market share, detailed analgesics market segments, market trends, and opportunities, and any further data you may need to thrive in the analgesics industry. This analgesics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiemetics and antinauseants refer to drugs that are used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. Antiemetic and antinauseant drugs prevent, control, or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu, or chemotherapy. These drugs reduced the symptoms of nausea or vomiting by blocking signal messages to the part of the brain that controls nausea and vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonists, antihistamines (h1 histamine receptor antagonists), cannabinoids, and benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists, and others. A dopamine antagonist also referred to as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others and is implemented in various sectors such as hospitals, medical centers, clinics, and research institutes. The global antiemetics and antinauseants market is segmented – 1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types 2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes The global antiemetics and antinauseants market size will grow from $7.76 billion in 2022 to $8.09 billion in 2023 at a compound annual growth rate (CAGR) of 4.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antiemetics and antinauseants is expected to grow to $9.12 billion in 2027 at a CAGR of 3.0%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatments to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by the Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac), and other serotonin 5-HT3 receptor types of antagonists. An increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for the market. Major players in the antiemetics and antinauseants market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Eli Lilly and Company, Merck, Eisai, Bristol-Myers Squibb, and SRS Pharmaceuticals . Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the antiemetics and antinauseants market. Despite the presence of a range of drugs, the practitioners prescribe similar drugs to treat patients with different conditions of nausea. The popularity of only a few drugs leads to lower demand for other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kinds of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specifically targeted sites in a controlled manner through Nanomedicine and Nano delivery systems. Nanomedicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drug manufacturers are inclining more toward the use of Nanomedicine or Nano drugs to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is the first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of the Food and Drug Administration Department of Health and Human Services, U.S. part 336, contains conditions that all Antiemetic and Antinauseant drugs are required to fulfil to remain in the market, such as definitions, regulations, and regulations related to the labelling of the antiemetic drug products. North America was the largest region in the drugs for antiemetics and antinauseants market in 2022. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the global antiemetics and antinauseants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antiemetics and antinauseants market research report are one of a series of new reports from The Business Research Company that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-opioid pain patch refers to a topical pain treatment that is non-opioid, non-systemic, and considered the only treatment available to provide prescription strength. It is used to relieve mild to moderate pain. The main non-opioid pain patches are lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches refer to a transdermal patch having analgesic action made of synthetic amide-type anesthetic lidocaine in a 5 percent aqueous base solution, which is used to aid treat some skin disorders' itching and pain. They are distributed by hospital pharmacies, retail pharmacies, and other channels for the treatment of various indications including musculoskeletal pain and neuropathic pain. The global non-opioid pain patch market is segmented - 1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 3) By Indication: Musculoskeletal Pain, Neuropathic Pain The global non-opioid pain patch market is expected to grow from $3.16 billion in 2022 to $3.34 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non-opioid pain patch market is expected to reach $4.03 billion in 2027 at a CAGR of 4.8%. The rising prevalence of chronic pain is expected to propel the growth of the non-opioid pain patch market going forward. Chronic pain refers to severe pain that lasts for an extended period or coexists with another medical condition. Non-opioid pain patches are used to relieve mild to moderate pain and treat headaches, muscle aches, arthritis, backaches, and other types of pain. For instance, in May 2021, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, In the United States, adults' prevalence of chronic pain ranged from 20.5% to 21.8% between 2019 and 2021, and their prevalence of high-impact chronic pain ranged from 6.9% to 7.8%. An estimated 51.6 million American adults (20.9%) reported having chronic pain in 2021, while 17.1 million (6.9%) reported having high-impact chronic pain. Therefore, the rising prevalence of chronic pain is propelling the non-opioid pain patch market. Major players in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Pfizer Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aurobindo Pharma Limited, Purdue Pharma L.P., Kyowa Kirin Co. Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Apotex Inc., Endo Pharmaceuticals plc, Lupin Limited, Amneal Pharmaceuticals LLC, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Private Limited, Mallinckrodt Pharmaceuticals LLC, IBSA Institut Biochimque SA, Teikoku Seiyaku ., Acorda Therapeutics Inc., Sorrento Therapeutics Inc., Veridian Healthcare LLC, Clarion Brands LLC, and Averitas Pharma Inc. Product innovation has emerged as a key trend gaining popularity in the non-opioid pain patch market. Major companies operating in the non-opioid pain patches market are developing innovative products to strengthen their position in the market. For instance, in June 2022, The Mentholatum Company Inc., a UK-based healthcare products manufacturer, launched Deep Relief Actiflex Patch, a drug-free pain patch. Deep Relief Actiflex Patch is a cooling hydrogel patch that contains water. It provides fast cooling and soothing relief when the water evaporates on the skin. This drug-free pain patch treats aches and pains in the muscles or joints. In August 2020, ACADIA Pharmaceuticals Inc., a US-based biopharmaceutical company acquired CerSci Therapeutics Inc. for a deal value of $52.5 million. With this purchase, ACADIA's clinical pipeline is strengthened by the addition of non-opioid pain medications with potential non-addictive qualities and fewer adverse effects than those associated with current opioid treatments. CerSci Therapeutics Inc. is a US-based pharmaceutical company that develops non-opioid pain therapies. North America was the largest region in the non-opioid pain patch market in 2022. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in non-opioid pain patch report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-opioid pain patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The non-opioid pain patch market consists of sales of aspirin, ibuprofen, and acetaminophen patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The non-opioid pain patch research report is one of a series of new reports from The Business Research Company that provides non-opioid pain patch market statistics, including the non-opioid pain patch industry's global market size, regional shares, competitors with non-opioid pain patch market share, detailed non-opioid pain patch market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain patch industry. This non-opioid pain patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.